Skip to main content
OpenTrials
Completed

NCT Number: NCT02513121

Dietary Treatment Study of Pediatric NAFLD

This is an investigator initiated study being conducted in equal numbers at two sites, University of California, San Diego (UC San Diego) and Emory University (EU). The purpose of this study is to understand the potential of a low sugar diet for the treatment of nonalcoholic fatty liver disease (NAFLD) in children. Forty boys with NAFLD will be randomly assigned to either an intervention group or a habitual diet control group. The intervention will be a low sugar diet for a period of 8 weeks. The effect of this dietary change will be assessed using advanced magnetic resonance imaging (MRI) testing to measure liver fat.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nonalcoholic Fatty Liver Disease Digestive System Diseases Fatty Liver Liver Diseases Non-alcoholic Fatty Liver Disease

Age range

11 year–16 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

University of California, San Diego, San Diego, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Boys age 11-16 years inclusive.
  • Clinical history consistent with NAFLD.
  • Biopsy-proven NAFLD
  • MRI measured Liver Proton Density Fat Fraction ≥10%
  • alanine aminotransferase (ALT) ≥ 45 u/L
  • No evidence of any other liver disease by clinical history or histological evaluation.
  • Written informed consent from parent or legal guardian.
  • Written informed assent from the child or adolescent.

Exclusion criteria

Exclusions will not be based upon gender, race, or ethnicity. Participants with a current history of the following conditions or any other health issues that make it unsafe for them to participate in the opinion of the Investigators will be excluded from the study:

  • History of significant alcohol intake (Alcohol Use Disorders Identification Test [AUDIT]) or inability to quantify alcohol consumption
  • Chronic use (more than 2 consecutive weeks) of medications known to cause hepatic steatosis or steatohepatitis in the past year.
  • The use of other known hepatotoxins within 120 days of baseline
  • History of total parenteral nutrition (TPN) use in the year prior to screening
  • History of bariatric surgery or planning to undergo bariatric surgery during the study duration
  • Significant depression
  • Non-compensated liver disease with any one of the following hematologic, biochemical, and serological criteria on entry into protocol:
  • Hemoglobin < 10 g/dL
  • White blood cell < 3,500 cells/mm
  • Neutrophil count < 1,500 cells/mm3 of blood
  • Platelets < 130,000 cells/mm3 of blood
  • Direct bilirubin > 1.0 mg/dL
  • Total bilirubin > 3 mg/dL
  • Albumin < 3.2 g/dL
  • International normalized ratio (INR) > 1.4
  • Evidence of other chronic liver disease
  • Children who are currently enrolled in a clinical trial or who received an investigational study drug or a medication with the intent to treat NAFLD/NASH in the past 60 days
  • Contraindications to MRI, e.g. metal in the eyes, implanted electronic devices, aneurysm clips, pacemaker, cochlear implants
  • Unable to have or complete the MRI exam due to body weight exceeding scanner table limit or girth exceeding scanner bore diameter
  • Subjects who are not able or willing to comply with the protocol or have any other condition that would impede compliance or hinder completion of the study, in the opinion of the investigator
  • Families with > 5 individuals
  • Failure to give informed consent

Treatment and study plan

Dietary modification

Other

The intervention is a modification of the family's habitual diet with a low sugar version of their diet.

Primary outcomes

  1. Change in Percentage of Liver Fat Measured by Magnetic Resonance Imaging (MRI) in the Intervention Group Compared to Change in the Control Group

    Time frame: Measurements done at baseline and week 8.

    The principal objective of this randomized and controlled pilot study is to evaluate whether 8 weeks of a low added sugar diet (<3%) in boys with NAFLD will change liver fat % measured by MRI.

Secondary outcomes

  1. Change in Alanine Aminotransferase (ALT) From Baseline to Week 8

    Time frame: Measurements done at baseline and week 8

  2. Change in Aspartate Aminotransferase (AST) From Baseline to Week 8

    Time frame: Measurements doen at baseline and week 8

  3. Change in Gamma-Glutamyl Transpeptidase (GGT) From Baseline to Week 8

    Time frame: Measurements done at baseline and week 8

  4. Change in Insulin From Baseline to Week 8

    Time frame: Measurements done at baseline and week 8

  5. Change in Homeostasis Model Assessment- Insulin Resistance (HOMA-IR) From Baseline to Week 8

    Time frame: Measurements done at baseline and week 8

    HOMA-IR was calculated as follows: fasting insulin (µU/mL) x fasting glucose (nmol/L)/22.5

  6. Change in Triglycerides From Baseline to Week 8

    Time frame: Measurements done at baseline and week 8

Sponsors and collaborators

Lead sponsor

University of California, San Diego

Other

Collaborators

  • Emory University
  • Nutrition Science Initiative

Registry information

Official study title

Randomized, Controlled Dietary Treatment Study of Pediatric NAFLD

Acronym: DTS

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Jul 31, 2015
Registry last updated
Jan 28, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.